Coagulation parameters measured after vector administration. Hemophilia A dogs were injected via the portal vein with 6 × 10¹² vg/kg (Elisa, ♦) or 2.7 × 10¹³ vg/kg (Junior, ▦) of AAV-cFVIII-104. (A) Whole blood was collected at various times after injection and assayed for whole-blood clotting times. Plasma samples from Junior were also assayed by Bethesda assay for FVIII neutralizing antibodies (- - -). (B-C) Plasma was collected and assayed for biologically active FVIII by Coatest and a one-stage assay, respectively. Both dogs received canine cryoprecipitate on days 0 and 1; Elisa received additional injections on days 5 and 6.